Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482461 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL4569135 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL7032005 | 0.93 | CYP2D6 (0.45) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL26655196 | 0.93 | CYP2D6 (0.45) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL26655167 | 0.93 | CYP2D6 (0.45) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL7166740 | 0.93 | CYP2D6 (0.45) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL18322206 | 0.87 | CYP2D6 (0.41) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL15727900 | 0.87 | CYP2D6 (0.43) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 | |
| SCHEMBL79261 | 0.87 | ALDH1A1 (0.46) | CYP2D6CYP1A2ACHEALDH1A1CYP3A4 | |
| SCHEMBL283868 | 0.87 | ACHE (0.46) | CYP2D6CYP1A2ACHEALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7875595-B2 | 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-10-08 | — | — | US | disclosed |
| US-7576069-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | CYP2D6 2193/4885CYP1A2 658/4885ACHE 1287/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | CYP2D6 2746/4885CYP1A2 1393/4885ACHE 1040/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CYP2D6 837/4885CYP1A2 341/4885ACHE 3840/4885 |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | CYP2D6 2308/4885CYP1A2 1966/4885ACHE 1075/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | CYP2D6 1452/4885CYP1A2 410/4885ACHE 733/4885 |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | CYP2D6 2199/4885CYP1A2 1227/4885ACHE 1817/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | CYP2D6 2199/4885CYP1A2 1227/4885ACHE 1817/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | CYP2D6 1452/4885CYP1A2 410/4885ACHE 733/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | CYP2D6 961/4885CYP1A2 901/4885ACHE 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.